JPH02501929A - 医学的使用 - Google Patents

医学的使用

Info

Publication number
JPH02501929A
JPH02501929A JP63508894A JP50889488A JPH02501929A JP H02501929 A JPH02501929 A JP H02501929A JP 63508894 A JP63508894 A JP 63508894A JP 50889488 A JP50889488 A JP 50889488A JP H02501929 A JPH02501929 A JP H02501929A
Authority
JP
Japan
Prior art keywords
treatment
compound
prevention
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63508894A
Other languages
English (en)
Japanese (ja)
Inventor
スターケ，インゲマル
ヴアツルマーク，ビヨルン
ヴエーネネン，カレルヴオ
Original Assignee
アクチエボラゲツト・ヘツスレ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクチエボラゲツト・ヘツスレ filed Critical アクチエボラゲツト・ヘツスレ
Publication of JPH02501929A publication Critical patent/JPH02501929A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP63508894A 1987-10-30 1988-10-27 医学的使用 Pending JPH02501929A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704248A SE8704248D0 (sv) 1987-10-30 1987-10-30 Medical use
SE8704248-7 1987-10-30

Publications (1)

Publication Number Publication Date
JPH02501929A true JPH02501929A (ja) 1990-06-28

Family

ID=20370069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63508894A Pending JPH02501929A (ja) 1987-10-30 1988-10-27 医学的使用

Country Status (9)

Country Link
EP (1) EP0339071A1 (ko)
JP (1) JPH02501929A (ko)
KR (1) KR890701587A (ko)
AU (1) AU2620388A (ko)
DK (1) DK322189A (ko)
HU (1) HU203663B (ko)
IL (1) IL88205A0 (ko)
SE (1) SE8704248D0 (ko)
WO (1) WO1989003833A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327796C (en) * 1987-07-16 1994-03-15 Jorg Senn-Bilfinger Diazoles
US5081253A (en) * 1989-12-21 1992-01-14 American Home Products Corporation Imidazo(4,5-c)pyridines as antiosteoporotic agents
US5464843A (en) * 1992-06-23 1995-11-07 G.D. Searle & Co. Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury
JPH11505524A (ja) * 1995-05-01 1999-05-21 藤沢薬品工業株式会社 イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途
GB9518552D0 (en) * 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
JP2016523944A (ja) 2013-07-10 2016-08-12 バイエル・ファルマ・アクティエンゲゼルシャフト ベンジル−１Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびその使用
CN106459090A (zh) 2014-02-19 2017-02-22 拜耳制药股份公司 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
EP3119777A1 (de) 2014-03-21 2017-01-25 Bayer Pharma Aktiengesellschaft Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
EP3137463A1 (de) * 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen
EP3137465A1 (de) * 2014-05-02 2017-03-08 Bayer Pharma Aktiengesellschaft 6-chlor-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase
JP2017514899A (ja) * 2014-05-02 2017-06-08 バイエル・ファルマ・アクティエンゲゼルシャフト ヘテロシクリル−およびヘテロアリール−置換イミダゾ［１，２−ａ］ピリジンおよびその使用
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
EP3227286B1 (de) 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
JP2018505885A (ja) 2015-02-05 2018-03-01 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロ［１，５−ａ］−ピリジン−３−カルボキサミドおよびその使用
WO2016124564A1 (de) 2015-02-05 2016-08-11 Bayer Pharma Aktiengesellschaft N-substituierte 8-[(2,6-difluorbenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamid-derivate als stimulatoren der löslichen guanylatcyclase (sgc) zur behandlung von kardiovaskulären erkrankungen
WO2018184976A1 (de) 2017-04-05 2018-10-11 Bayer Pharma Aktiengesellschaft Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068378B1 (en) * 1981-06-26 1986-03-05 Schering Corporation Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4468400A (en) * 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
DE3446778A1 (de) * 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4725601A (en) * 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
EP0228006A1 (en) * 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof

Also Published As

Publication number Publication date
DK322189D0 (da) 1989-06-28
AU2620388A (en) 1989-05-23
SE8704248D0 (sv) 1987-10-30
WO1989003833A1 (en) 1989-05-05
IL88205A0 (en) 1989-06-30
DK322189A (da) 1989-06-28
EP0339071A1 (en) 1989-11-02
KR890701587A (ko) 1989-12-21
HU203663B (en) 1991-09-30
HUT51138A (en) 1990-04-28

Similar Documents

Publication Publication Date Title
JPH02501929A (ja) 医学的使用
AU2007345952B2 (en) Positively charged water-soluble prodrugs of 1H-imidazo[4, 5-c]quinolin-4-amines and related compounds with very high skin penetration rates
TW568907B (en) Imidazo pyridine derivatives for inhibition of gastric acid secretion
RU99120178A (ru) Соединения для ингибирования секреции желудочной кислоты
CN1694711A (zh) 扩大维生素剂量范围的方法
EP1902054A1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
US4843069A (en) Medicament formulations containing ruthenium compounds with an antitumoral action
EP0318330A3 (en) Glutathione esters for treating ventricular arrhythmia
US6544995B1 (en) Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
US5637311A (en) Zinc(II) complexes and methods related thereto
US5354773A (en) Use of bafilomycine and derivatives to treat bone diseases
CN101605763B (zh) 防辐射化合物及相关方法
EP0357550A2 (en) New use of 5-heteroaryl- or 5-aryl-substituted imidazo [2,1-a] isoquinolines
FR2873118A1 (fr) Derives de pyrido-pyrimidine, leur application en therapeutique
EP0373663A2 (en) Castanospermine esters in the inhibition of tumor metastasis
JPH02501930A (ja) 薬学的化合物のための新規な用途
JPH10500977A (ja) ピリジルビスホスホン酸エステルよりなる治療用活性薬剤
AU2922389A (en) Improving toxicity profiles in chemotherapy
JP4780834B2 (ja) 新規なプテリン抗新生物薬
US11319273B2 (en) Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia
EP0500953B1 (en) Antineoplastic effect potentiator and antineoplastic agent
CN103687849A (zh) (-)-石杉碱甲方法及相关组合物和治疗方法
EP0561597B1 (en) New derivatives of physostigmine, their use and pharmaceutical formulations containing them
EP0870503B1 (en) use of vitamin D derivatives for the manufacture of a medicament for treating MALIGNANT TUMOR METASTASIS
JP2000302762A (ja) 放射線および化学療法における感受性増強剤であるグリシジアゾール金属塩、並びにそれらの製造方法および使用